NIPH Clinical Trials Search

HPP Japan

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Cancer and hematologic malignancies (excluding non-melanoma skin cancer), acute hematologic disorder
Date of first enrollment	21/06/2026
Target sample size	2000
Countries of recruitment
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	Identification of phenotypes associated with disease onset and progression, survival, healthy life expectancy, age-related changes, and major health events
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 40age old
Age maximum	< 70age old
Gender	Both
Include criteria	1) Men and women aged 40-69 at pre-screening 2) Individuals who are capable of visiting the CTC at baseline and have a will to continue to visit the CTC throughout the follow-up period at pre-screening 3) Individuals who are able and willing to sign a consent form at the time of the baseline visit to the CTC 4) Own a smartphone capable of downloading the app for this project and have the ability to use it
Exclude criteria	1)Individuals who are pregnant or within 2 months after pregnancy 2)Individuals who are on infertility treatment or within 2 months after the last infertility treatment (women only) 3)Individuals who have malignancy, recurrent or metastatic, that is either untreated or undergoing treatment, or a certain period of time has not passed since the last treatment at pre-screening (for chemotherapy, less than 1 year from the date of the last administration; for radiotherapy, less than 2 months from the day of the last exposure) 4)Individuals who have a history of chronic or acute hepatitis 5)Individuals who have a history of HIV infection, hepatitis B or C virus infection 6)Individuals who have diagnosed with liver cirrhosis 7)Individuals who are under dialysis treatment 8)Individuals who have poorly controlled disease or symptoms (with unstable symptoms and clinical laboratory test results despite treatments) 9)Individuals who are not capable of continued participation in this study due to impaired cognitive, intellectual, or mental function